文献速递外周动脉疾病

GLP-1受体激动剂与糖尿病下肢旁路术后生存改善相关

GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients.
PubMed 文献 · Ann Vasc Surg · 2025-08-16

该回顾性研究纳入2017至2024年多院区322例糖尿病下肢旁路术患者,GLP-1受体激动剂使用率从8.2%升至18.8%。用药组2年生存率更高(94.7% vs. 71.8%),调整后死亡风险降低(aHR=0.09),2年无MACE生存率也更高(100% vs. 88.6%)。

要点

  • GLP-1受体激动剂使用与下肢旁路术后2年生存改善独立相关。
  • 用药组2年无主要不良心血管事件生存率显著更高。
  • 两组主要不良肢体事件无显著差异,需进一步研究确认。

核心结论

  • GLP-1受体激动剂使用与糖尿病下肢旁路术后生存改善及无MACE生存改善相关。

研究设计与样本

  • 回顾性多院区研究,纳入2017至2024年322例糖尿病下肢旁路术患者,共339次旁路手术。

主要发现

  • GLP-1受体激动剂使用率从8.2%升至18.8%(P=0.001)。
  • 用药组(n=38,11.2%)更年轻(65.5 vs. 69.9岁,P=0.003),BMI更高(29.6 vs. 27.2 kg/m2,P<0.001)。
  • 用药组2年生存率更高(94.7% vs. 71.8%,P=0.004)。
  • 调整分析显示GLP-1受体激动剂使用与死亡风险降低相关(aHR=0.09,95%CI 0.01-0.66,P=0.02)。
  • 用药组2年无MACE生存率更高(100% vs. 88.6%,P=0.046),无主要不良肢体事件生存率两组相似。

临床怎么用

  • 对合并动脉粥样硬化性心血管疾病(含外周动脉疾病)的糖尿病下肢旁路术患者,可考虑使用GLP-1受体激动剂以改善术后生存。

局限性

  • 回顾性设计,样本量有限,随访时间中位数18个月,需进一步研究确认结果差异原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American Diabetes Association recommends the use of glucagon-like-peptide-1 receptor agonists (GLP1-RAs) (e.g., Ozempic) for patients with atherosclerotic cardiovascular disease, including peripheral artery disease. We hypothesized increasing the use of GLP1-RAs would be associated with improved outcomes after bypass. METHODS: Retrospective review of diabetic patients undergoing infrainguinal bypass at a multihospital institution between 2017 and 2024 was conducted, including patient characteristics, operative details, and outcomes. The primary outcome was survival. Secondary outcomes included perioperative complications, major adverse limb events, major adverse cardiovascular events (MACE), and metabolic changes. Kaplan-Meier and Cox regression evaluated outcomes. RESULTS: A total of 322 patients (62.5% male, 78.8% White, median age 68 [61-76] years) underwent 339 bypasses. GLP1-RA use increased from 8.2% to 18.8% during the study period (P = 0.001). Patients on a GLP1-RA (n = 38, 11.2%) were younger (65.5 [57.0-71.0] vs. 69.9 [62.0-77.0] years, P = 0.003) and had a higher body mass index (29.6 [26.9-33.3] vs. 27.2 [23.3-31.1] kg/m2, P < 0.001). Median follow-up was 18 [6-39] months. Improved survival at 2 years was seen among patients on a GLP1-RA (94.7% vs. 71.8%, P = 0.004). On adjusted analysis, GLP1-RA use was associated with reduced mortality (adjusted hazard ratio = 0.09, 95% confidence interval 0.01-0.66, P = 0.02). Freedom from MACE at 2 years was greater among patients on a GLP-1-RA (100% vs. 88.6%, P = 0.046). Freedom from major adverse limb events was similar between groups. CONCLUSION: GLP1-RA use is increasingly common in patients undergoing lower extremity bypass and was associated with significantly improved postoperative survival and freedom from MACE. Further studies are required to confirm reasons for differences in outcomes.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Yehualashet E, Mazroua MS, Narvaez E, et al. GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients. Ann Vasc Surg. 2025. PMID: 40825437. doi:10.1016/j.avsg.2025.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。